Atom | Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)

Funder: National Institutes of Health

Funding Amounts: Up to $1,000,000 direct costs/year; max project period 5 years; NIA expects to fund 4–5 awards in FY26

Summary: Supports rigorous preclinical testing of repurposed and investigational drugs or drug combinations for Alzheimer’s disease and related dementias using mouse or cell-based models; clinical trials are not allowed.

Key Information: Applications must include both computational and experimental approaches; projects proposing only computational work or new drug development are not responsive.

Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)

Sign in to see full grant listing